Search

Duvelisib

can produce a broad adaptative and innate immune cell inhibitory activity. … All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]

APT20TTMG

APT20TTMG is a synthetic DNA that modulates U1 small nuclear ribonucleoprotein misassembly.

Fimasartan

It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.

Tezacaftor

[L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class.

Potassium triiodide

Osbond acid

Menatetrenone

Menatetrenone has been used in trials studying the treatment of Diabetes, Osteoporosis, Prediabetic State, and Hepatocellular Carcinoma.

Lefamulin

A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. … Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia.

Terpin hydrate

It was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate

Benralizumab

[A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019] … Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils